Consensus Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.50 USD | +8.36% |
|
+0.74% | -31.74% |
| 03:05pm | Boston Scientific Corporation, Q1 2026 Earnings Call, Apr 22, 2026 | |
| 01:59pm | Boston Scientific cuts 2026 profit forecast, trims revenue growth view | RE |
Evolution of the Average Target: Boston Scientific Corporation
Evolution of the Target Price: Boston Scientific Corporation
Changes in Analyst Recommendations: Boston Scientific Corporation
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +60.87% | |||||
| +23.41% | |||||
| +31.07% | |||||
| +30.05% | |||||
| +41.94% | |||||
| +20.85% | |||||
| +31.61% | |||||
| +25.57% | |||||
| +15% | |||||
| +32.15% | |||||
| Average | +31.25% | |||||
| Weighted average by Cap. | +31.59% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Barclays | |
| Stifel Nicolaus | |
| Baird | |
| Truist Securities | |
| RBC Capital Markets | |
| BTIG | |
| Mizuho Securities | |
| Goldman Sachs | |
| Citigroup | |
| Evercore ISI | |
| Rothschild & Co Redburn | |
| Jefferies & Co. | |
| Raymond James | |
| Leerink Partners | |
| China Merchants | |
| Argus | |
| Deutsche Bank Securities | |
| Needham & Co. | |
| UBS | |
| TD Cowen | |
| JPMorgan Chase | |
| Wells Fargo Securities | |
| Wolfe Research | |
| Bernstein | |
| Piper Sandler | |
| Oppenheimer | |
| Canaccord Genuity | |
| Daiwa Securities | |
| Morgan Stanley | |
| CICC Research | |
| Nephron Research | |
| William O'Neil & Co | |
| Redburn Atlantic | |
| CL King | |
| BofA Securities | |
| SVB Leerink | |
| Credit Suisse | |
| Atlantic Equities |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BSX Stock
- Consensus Boston Scientific Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition